WP-0512-003: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Grants and Contracts Details

StatusActive
Effective start/end date4/25/22 → 2/19/25

Funding

  • Woolsey Pharmaceuticals Incorporated: $82,882.00